Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders

Multiple Sclerosis

Volumn 23, Issue 10, 2017, Pages 1377-1384

  Montcuquet, Alexis ^a,b   Collongues, Nicolas ^c   Papeix, Caroline ^d   Zephir, Helene ^e   Audoin, Bertrand ^f   Laplaud, David ^g   Bourre, Bertrand ^h   Brochet, Bruno ⁱ   Camdessanche, Jean Philippe ^j   Labauge, Pierre ^k   Moreau, Thibault ^l   Brassat, David ^m   Stankoff, Bruno ⁿ   de Seze, Jerome ^c   Vukusic, Sandra ^a,o,p   Marignier, Romain ^a,o,p  

^a HÔPITAL NEUROLOGIQUE   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIV LILLE   (France)

^f TIMONE HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m CHU PURPAN   (France)

ⁿ HÔPITAL TENON   (France)

^o LYON NEUROSCIENCE RESEARCH CENTER   (France)

^p UNIVERSITÉ LYON 1   (France)

more..

Author keywords

Aquaporin 4; myelin oligodendrocyte glycoprotein; neuromyelitis optica; treatment response

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; RECURRENCE RISK; RECURRENT DISEASE; SCORING SYSTEM; SERODIAGNOSIS;

EID: 85027870837     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516678474     Document Type: Article

References (31)

1. Lennon VA, Wingerchuk DM, Kryzer TJ. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106–2112.
2. Lennon VA. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202(4): 473–477.
3. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11(6): 535–544.
4. Misu T, Höftberger R, Fujihara K. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125(6): 815–827.
5. Wingerchuk DM, Banwell B, Bennett JL. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85(2): 177–189.
6. Wingerchuk DM, Lennon VA, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805–815.
7. Marignier R, Bernard-Valnet R, Giraudon P. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80(24): 2194–2200.
8. Sato DK, Callegaro D, Lana-Peixoto MA. Seronegative Neuromyelitis Optica Spectrum—The challenges on disease definition and pathogenesis. Arq Neuropsiquiatr 2014; 72(6): 445–450.
9. Kitley J, Waters P, Leite MI. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014; 71(3): 276–283.
10. Kimbrough DJ, Fujihara K, Jacob A. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 2012; 1(4): 180–187.
11. Pittock SJ, Lennon VA, Mandrekar J. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol 2013; 12(6): 554–562.
12. Araki M, Matsuoka T, Miyamoto K. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 2014; 82(15): 1302–1306.
13. Tradtrantip L, Zhang H, Saadoun S. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012; 71(3): 314–322.
14. Androdias G, Maillet D, Marignier R. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76(13): 1168–1172.
15. Jacob A, Matiello M, Weinshenker BG. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol 2009; 66(9): 1128–1133.
16. Huh SY, Kim SH, Hyun JW. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71(11): 1372–1378.
17. Mealy MA, Wingerchuk DM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurol 2014; 71(3): 324–330.
18. Höftberger R, Sepulveda M, Armangue T. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Neurology 2015; 21(7): 866–874.
19. Collongues N, Papeix C, Marignier R. Nosology and etiologies of acute longitudinally extensive transverse myelitis. Rev Neurol 2014; 170(1): 6–12.
20. Tackley G, O’Brien F, Palace J. Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Mult Scler Relat Disord 2016; 7: 21–25.
21. Chiarelli LR, Molinaro M, Libetta C. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Brit J Clin Pharmaco 2010; 69(1): 38–50.
22. Sombogaard F, Peeters AM, Baan CC. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009; 31(5): 549–556.
23. Cree BA, Lamb S, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64(7): 1270–1272.
24. Kim SH, Kim W, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011; 68(11): 1412–1420.
25. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51(4): 1219–1220.
26. Costanzi C, Matiello M, Lucchinetti CF. Azathioprine tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77(7): 659–666.
27. Sellner J, Boggild M, Clanet M. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17(8): 1019–1032.
28. Trebst C, Jarius S, Berthele A. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1): 1–16.
29. Jeong IH, Park B, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016; 22: 329–339.
30. Jarius S, Ruprecht K, Kuempfel T. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflamm 2012; 9(1): 14.
31. Bernard-Valnet R, Liblau RS, Vukusic S. Neuromyelitis optica: A positive appraisal of seronegative cases. Eur J Neurol. Epub ahead of print 16 February 2015. DOI: 10.1111/ene.12679.